Loading...

Nanalysis Scientific Corp.

NSCIFPNK
Technology
Hardware, Equipment & Parts
$0.11
$0.00(0.00%)
U.S. Market is Open • 15:00

Nanalysis Scientific Corp. Fundamental Analysis

Nanalysis Scientific Corp. (NSCIF) shows moderate financial fundamentals with a PE ratio of -3.38, profit margin of -14.10%, and ROE of -43.91%. The company generates $0.0B in annual revenue with strong year-over-year growth of 59.82%.

Key Strengths

PEG Ratio-0.04

Areas of Concern

ROE-43.91%
Operating Margin-9.38%
Cash Position3.89%
Current Ratio0.97
We analyze NSCIF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -22.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-22.7/100

We analyze NSCIF's fundamental strength across five key dimensions:

Efficiency Score

Weak

NSCIF struggles to generate sufficient returns from assets.

ROA > 10%
-14.73%

Valuation Score

Excellent

NSCIF trades at attractive valuation levels.

PE < 25
-3.38
PEG Ratio < 2
-0.04

Growth Score

Excellent

NSCIF delivers strong and consistent growth momentum.

Revenue Growth > 5%
59.82%
EPS Growth > 10%
25.00%

Financial Health Score

Weak

NSCIF carries high financial risk with limited liquidity.

Debt/Equity < 1
1.31
Current Ratio > 1
0.97

Profitability Score

Weak

NSCIF struggles to sustain strong margins.

ROE > 15%
-4390.56%
Net Margin ≥ 15%
-14.10%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is NSCIF Expensive or Cheap?

P/E Ratio

NSCIF trades at -3.38 times earnings. This suggests potential undervaluation.

-3.38

PEG Ratio

When adjusting for growth, NSCIF's PEG of -0.04 indicates potential undervaluation.

-0.04

Price to Book

The market values Nanalysis Scientific Corp. at 1.43 times its book value. This may indicate undervaluation.

1.43

EV/EBITDA

Enterprise value stands at 0.48 times EBITDA. This is generally considered low.

0.48

How Well Does NSCIF Make Money?

Net Profit Margin

For every $100 in sales, Nanalysis Scientific Corp. keeps $-14.10 as profit after all expenses.

-14.10%

Operating Margin

Core operations generate -9.38 in profit for every $100 in revenue, before interest and taxes.

-9.38%

ROE

Management delivers $-43.91 in profit for every $100 of shareholder equity.

-43.91%

ROA

Nanalysis Scientific Corp. generates $-14.73 in profit for every $100 in assets, demonstrating efficient asset deployment.

-14.73%

Following the Money - Real Cash Generation

Operating Cash Flow

Nanalysis Scientific Corp. generates limited operating cash flow of $3.00M, signaling weaker underlying cash strength.

$3.00M

Free Cash Flow

Nanalysis Scientific Corp. produces free cash flow of $1.36M, offering steady but limited capital for shareholder returns and expansion.

$1.36M

FCF Per Share

Each share generates $0.01 in free cash annually.

$0.01

FCF Yield

NSCIF converts 9.43% of its market value into free cash.

9.43%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.38

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.04

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.43

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.41

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.31

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.97

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.44

vs 25 benchmark

ROA

Return on assets percentage

-0.15

vs 25 benchmark

ROCE

Return on capital employed

-0.18

vs 25 benchmark

How NSCIF Stacks Against Its Sector Peers

MetricNSCIF ValueSector AveragePerformance
P/E Ratio-3.3835.29 Better (Cheaper)
ROE-43.91%1050.00% Weak
Net Margin-14.10%5920942259.00% Weak
Debt/Equity1.310.46 Weak (High Leverage)
Current Ratio0.974.96 Weak Liquidity
ROA-14.73%-295004.00% (disorted) Weak

NSCIF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Nanalysis Scientific Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

172.04%

Industry Style: Growth, Innovation, High Beta

High Growth

EPS CAGR

-310.13%

Industry Style: Growth, Innovation, High Beta

Declining

FCF CAGR

108.95%

Industry Style: Growth, Innovation, High Beta

High Growth

Fundamental Analysis FAQ